LH

T2S&P 500Health Care (XLV)Value (IWD)Low Volatility (SPLV)

Labcorp Holdings Inc.

Next est. report 2026-10-28 · BMO

Data Owners '25: Healthcare, Claims & Clinical Data Diagnostics '26: Broad Diagnostic Platforms & Labs MedTech Long '24: Lab Research & Trials MedTech Long '26: CROs MedTech Long '26: Diagnostics & Early Detection

Loading…

Loading chart…

Overview

Labcorp Holdings Inc. (LH) provides vital diagnostic laboratory services, representing approximately 78% of its revenue, and biopharmaceutical laboratory servic

Labcorp Holdings Inc. (LH) provides vital diagnostic laboratory services, representing approximately 78% of its revenue, and biopharmaceutical laboratory services, accounting for roughly 22%. The company serves medical professionals, healthcare facilities, pharmaceutical firms, and patients. Labcorp is strategically expanding specialty testing in areas like oncology and neurology, growing its consumer health offerings, and leveraging AI to enhance operations and customer experience.

Key Inputs And Sourcing

1. Labor (Clinical Lab Technologists & Phlebotomists)

Not in registryaccess=api

labor · 29-2011, 29-2012 · United States · unknown

Source Median annual wage for clinical laboratory technologists and technicians was $62,930 in May 2025.

Confidence: high

2. Diagnostic Reagents

Not in registry

component · 382219 · Global (U.S., Europe, Asia) · unknown

Source Labcorp's supply chain involves sourcing reagents. HS code 382219 for diagnostic or laboratory reagents.

Confidence: high

3. Medical Consumables & Specimen Collection Materials

Not in registry

component · 15.07 · Global (U.S., Europe, Asia) · unknown

Source Labcorp's supply chain involves sourcing consumables and specimen-collection materials. Commodity code 15.07 for Medical Supplies and Equipment includes patient care supplies.

Confidence: high

4. Logistics & Transportation Services

Not in registry

logistics · containerized-freight-index · Global · unknown

Source Labcorp's supply chain involves logistics services. Containerized Freight Index tracks shipping costs.

Confidence: high

5. Electricity

Not in registryaccess=api

energy · electricity/retail-sales (sectorid=IND) · United States · unknown

Source U.S. average industrial electricity price was 9.77 ¢/kWh in July 2026.

Confidence: high

6. Laboratory Instruments & Equipment (parts & maintenance)

Not in registry

component · 90189084 · Global · unknown

Source Labcorp's operations require instruments. HS code 90189084 for medical instruments and appliances.

Confidence: medium

7. Software & IT Services

Not in registry

other · Global · unknown

Source Labcorp is increasing the use of advanced technologies across the company, including AI and digital platforms.

Confidence: medium

8. Packaging Materials

Not in registry

packaging · Global · unknown

Source Labcorp's global supply chain ensures supply for operations, including production of customized clinical trial kits.

Confidence: medium

Industry Publications

Fierce Biotech (CRO section) (fiercebiotech.com) — Monitors news and trends in the Contract Research Organization (CRO) market, clinical trials, and biotech funding, directly relevant to Labcorp's Biopharma Laboratory Services segment.
BioPharm International (biopharminternational.com) — Provides scientific and business insights on biopharmaceutical R&D, manufacturing, and regulatory issues, crucial for understanding Labcorp's biopharma services.
SelectScience (Clinical Diagnostics) (selectscience.net) — Covers clinical laboratory diagnostics, cutting-edge lab techniques, medical technologies, biomarkers, and precision medicine, directly impacting Labcorp's Diagnostics segment.
Medical Device & Diagnostic Industry (MD&DI) (mddionline.com) — Focuses on medical devices and in vitro diagnostic products, including regulations and market requirements, which are key for Labcorp's diagnostic offerings.
Clinical Lab Products (clpmag.com) — Focuses on clinical diagnostics and the business of clinical labs, covering technology, regulation, reimbursement, and M&A across IVD and lab services.

Economic Data Watch

1. FRED — National Health Expenditure Accounts (NHEA)

Not in registryaccess=api

Metric/field Total Health Expenditures

Cadence quarterly

Why it matters Overall healthcare spending indicates the market size and health for diagnostic services, directly impacting Labcorp's addressable market.

Signal to watch Increasing total health expenditures signals a growing market for Labcorp's services.

Confidence: low

2. BLS — Labor Force Statistics from the Current Population Survey

Matched (medium)lab_headcount · access=api

Metric/field Unemployment Rate (UNRATE)

Cadence monthly

Why it matters The unemployment rate affects consumer ability to pay for healthcare services (co-pays, deductibles, direct-to-consumer testing) and overall economic sentiment impacting healthcare utilization.

Signal to watch Decreasing unemployment rate suggests stronger consumer financial health and potentially higher utilization of healthcare services.

Confidence: high

3. FRED — Gross Domestic Product

Not in registryaccess=api

Metric/field Real Gross Domestic Product (GDPC1)

Cadence quarterly

Why it matters Real GDP growth is a broad indicator of economic health, which can influence R&D spending by biopharmaceutical companies (impacting BLS segment) and overall healthcare budgets.

Signal to watch Sustained or increasing real GDP growth indicates a favorable economic environment for Labcorp's diversified businesses.

Confidence: high

4. BLS — Consumer Price Index

Not in registryaccess=api

Metric/field Consumer Price Index for All Urban Consumers: All Items (CPIAUCSL)

Cadence monthly

Why it matters Inflation, as measured by CPI, impacts Labcorp's operating costs (labor, supplies, logistics) and can influence pricing strategies and margin pressure.

Signal to watch Stable or declining CPI growth suggests more manageable operating costs and potentially less pressure on margins.

Confidence: high

5. FRED — Federal Funds

Not in registryaccess=api

Metric/field Federal Funds Effective Rate (FEDFUNDS)

Cadence daily

Why it matters The federal funds rate influences borrowing costs for Labcorp's debt and impacts capital allocation decisions, including acquisitions and share repurchases.

Signal to watch Stable or declining federal funds rate can reduce interest expenses and support capital deployment strategies.

Confidence: high

Free Alt Data Watch

1. ClinicalTrials.gov — Clinical Trial Registry

Not in registry

Metric/field Number of new studies initiated (Sponsor: Labcorp/Covance)

Cadence monthly

Why it matters Labcorp's Biopharma Laboratory Services (BLS) segment is heavily involved in clinical trials. Tracking new trial registrations or status changes for relevant therapeutic areas or sponsors can signal future demand for their services.

Signal to watch Increasing number of new clinical trials sponsored or collaborated by Labcorp/Covance indicates strong demand and pipeline for BLS.

Confidence: high

2. FDA — Medical Device Approvals and Clearances

Not in registry

Metric/field Count of new FDA 510(k) clearances/PMA approvals for diagnostic tests relevant to Labcorp's portfolio

Cadence daily

Why it matters Labcorp frequently launches new diagnostic tests (e.g., ColoSense, Plasma Detect Genome MRD). Tracking FDA clearances/approvals for diagnostic devices, especially in specialty areas, indicates innovation and market expansion.

Signal to watch Consistent or increasing number of FDA approvals for Labcorp's diagnostic tests signals strong R&D and market potential.

Confidence: high

3. USASpending.gov — Federal Contract Awards

Not in registryaccess=api

Metric/field Total value and number of new federal contract awards to Labcorp Holdings Inc.

Cadence daily

Why it matters Labcorp was recently awarded a Department of Defense contract. Monitoring federal contract awards can indicate growth in government business and strategic partnerships.

Signal to watch Increasing value and number of federal contract awards suggest expanding government and institutional business for Labcorp.

Confidence: high

4. Google Trends — Search Interest

Not in registry

Metric/field Relative search interest volume for 'ColoSense', 'Labcorp OnDemand', 'Alzheimer's blood test', 'MRD testing' (United States)

Cadence weekly

Why it matters Tracks public and physician interest and awareness in Labcorp's key diagnostic technologies and consumer offerings, signaling potential market adoption and demand.

Signal to watch Rising search interest for these terms indicates increasing awareness and potential demand for Labcorp's specialty and consumer tests.

Confidence: medium

5. Apple App Store / Google Play — App Rankings / Downloads

Not in registry

Metric/field MyLabcorp app rank in Health & Fitness category (US) or estimated download trend

Cadence daily

Why it matters The MyLabcorp app is a strategic priority for consumer engagement and digital experience. Tracking its performance indicates consumer adoption and engagement with Labcorp's digital offerings.

Signal to watch Improving app rankings or increasing download trends suggest successful consumer adoption and engagement with MyLabcorp.

Confidence: medium

Paid Alt Data Watch

1. IQVIA — Medical Claims Data

Matchediqvia_medical_claims · access=file · map_only

Metric/field CPT code utilization for key molecular diagnostic tests (e.g., specific codes for liquid biopsy, MRD, MCED, ColoSense)

Cadence monthly

Why it matters Provides granular, independent data on actual test utilization, market share, and reimbursement trends for Labcorp's high-growth specialty diagnostics.

Signal to watch Increasing CPT code utilization for Labcorp's specialty tests indicates strong market adoption and revenue growth in these areas.

Confidence: high

2. Similarweb — Web & App Insights

Matched (medium)similarweb_website_traffic_engagement · access=file · map_only

Metric/field Total unique visitors and engagement metrics for labcorp.com, ir.labcorp.com, and MyLabcorp app active users/sessions (US)

Cadence monthly

Why it matters Website traffic and app usage data can indicate investor interest, customer engagement, and the growth of Labcorp's consumer business and digital initiatives.

Signal to watch Increasing unique visitors and active users/sessions suggest growing customer and investor interest and successful digital strategy execution.

Confidence: high

3. Definitive Healthcare — PhysicianView / HospitalView

Not in registry

Metric/field Physician referral volumes to Labcorp, hospital lab outsourcing agreements, and test volumes from partner health systems

Cadence quarterly

Why it matters Labcorp is actively pursuing hospital and regional lab partnerships. This data can track the impact of these collaborations on referral patterns and test volumes.

Signal to watch Increasing physician referral volumes to Labcorp and growing test volumes from partner health systems indicate successful partnership expansion.

Confidence: high

4. Truveta — EHR Data / Linked Claims

Matched (medium)truveta_genomics · access=file · map_only

Metric/field Patient diagnoses and test orders for Labcorp's specialty tests (e.g., oncology, neurology, autoimmune) within Truveta's network

Cadence daily

Why it matters Provides real-time insights into clinical practice patterns, adoption of new diagnostics, and patient outcomes, offering a granular view of Labcorp's market penetration.

Signal to watch Increasing orders for Labcorp's specialty tests within the EHR data indicates growing clinical adoption and market share.

Confidence: medium

5. Hatched Analytics — Card / Transaction Data

Matched (medium)hatched_analytics_ticker_level_transaction_digital_kpi_feeds · access=file · map_only

Metric/field Consumer spending on Labcorp services (e.g., Labcorp OnDemand, patient responsibility payments) by transaction volume and value

Cadence weekly

Why it matters Directly measures consumer-initiated testing and patient out-of-pocket spending, providing insights into the growth and profitability of Labcorp's consumer health segment.

Signal to watch Increasing transaction volume and value for Labcorp services indicates strong consumer demand and revenue growth in the direct-to-consumer segment.

Confidence: medium

Search Keywords Brand Product

ColoSense
Plasma Detect Genome MRD
NASHnext
Marker by Labcorp Genetic Health Panel
MyLabcorp app
Labcorp OnDemand
diagnostic laboratory services
biopharma laboratory services
specialty testing
oncology testing
neurology testing
consumer health testing
AI in healthcare
health system partnerships
clinical trials
central laboratories

Search Keywords Event Phrases

Labcorp Q2 2026 earnings
Labcorp guidance update

Search Keywords Policy Regulatory

PAMA
RESULTS Act
Medicare coverage diagnostics

What They Do (Plain English & Analogies): Labcorp is like a central laboratory for doctors, hospitals, and drug companies. When your doctor needs to know what's going on inside your body, like checking your blood for cholesterol or diagnosing a disease, Labcorp runs those tests to give clear and accurate results. They also act as a crucial partner for pharmaceutical companies, helping them develop new medicines by performing tests during clinical trials. So, whether it's for your personal health diagnosis or for bringing new drugs to market, Labcorp provides the essential lab services and data needed for informed decisions.
Very Brief History: Labcorp's journey began in 1969 as Biomedical Reference Laboratories in Burlington, North Carolina. The company, as it is largely known today, was formed in 1995 through the merger of Roche Biomedical Laboratories and National Health Laboratories, establishing a national diagnostics platform. A significant expansion occurred in 2015 with the acquisition of Covance, which broadened Labcorp's reach into drug development services. In 2023, Labcorp spun off its clinical development business, Fortrea, to focus on its core diagnostics and lab-enabled drug development services.
"Street Stereotype": Labcorp is generally perceived by investors and analysts as a diversified leader in laboratory services, combining a massive diagnostic testing network with significant central laboratory capabilities for drug development. While it benefits steadily from rising overall clinical volume and strategic acquisitions, its broad diagnostic hospital network is seen as softening its "pure-play CRO" (Contract Research Organization) torque, meaning it's not solely focused on clinical trials like some competitors. It is viewed as a stable, large-scale player in healthcare testing and research, increasingly leveraging technology like AI.
Subsidiaries On Linked In*: {"subsidiaries":[]}
Customer Sectors & Example Clients: Labcorp's customers span various sectors including medical professionals (physicians and other healthcare providers), healthcare facilities (hospitals and health systems), pharmaceutical and biotechnology firms (pharmaceutical, biotechnology, medical device, and diagnostics companies, and CROs), scientific investigators (researchers and academic institutions), patients and consumers (individuals seeking direct-to-consumer testing), governmental agencies, employers, and crop protection and chemical companies. Example clients and partners mentioned include Fox Chase Cancer Center, AstraZeneca, Parkview Health, Tribal Diagnostics, the Department of Defense, Epic, Illumina, Merck, Amazon Web Services (AWS), Datavant, and Optum.ai.
New Customers / Segments They'Re Targeting: Labcorp is actively targeting several new customer segments and expanding its reach. They are focused on strengthening their leadership in specialty testing across areas like oncology, neurology, autoimmune disease, and women's health. They are also aiming to be a partner of choice for health systems and regional and local laboratories, as evidenced by recent acquisitions like select outreach laboratory services from Parkview Health and Tribal Diagnostics. Furthermore, Labcorp is significantly growing its consumer business through offerings like Labcorp OnDemand and the MyLabcorp app, targeting individuals seeking consumer-initiated testing and personalized health insights.
Sales Geographies And Expansion Plans: Labcorp operates one of the largest clinical laboratory networks globally, with operations in over 100 countries, although its primary operations are in the U.S. Its global performing and processing labs are located around the world, with more than 30 U.S. reference and specialty labs dedicated to diagnostic testing and over 75 global labs primarily dedicated to research, development, and clinical trial testing. The company serves customers in the Americas, Europe, and Asia-Pacific. Regarding expansion plans, Labcorp is actively pursuing acquisitions and partnerships with health systems and regional/local laboratories within the U.S. to expand its patient and provider networks and increase access to its test portfolio, indicating an "active pipeline of hospitals and regional local laboratory deals." They were also recently awarded a Department of Defense contract to provide laboratory testing for service members and their families across military hospitals worldwide. While the transcript does not explicitly detail new country-level geographic sales expansion plans, the ongoing growth in its Biopharma Laboratory Services (BLS) segment, which has a global footprint, implies continued expansion and service delivery in existing international markets for clinical trials.
How Key Themes May Help/Hurt: The buildout of the "MedTech Long '26: Diagnostics & Early Detection" theme is largely beneficial for Labcorp. Labcorp's extensive logistics network makes it crucial infrastructure for deploying advanced blood-based cancer and Alzheimer's tests to the mass market. Accelerating technological advancements in genomics, AI, and multiomics directly supports Labcorp's strategy of expanding its specialty testing portfolio, particularly in oncology and neurology. The increasing global prevalence of chronic diseases and an aging population drives sustained demand for advanced diagnostic solutions, which Labcorp is well-positioned to meet. Favorable regulatory developments, such as expanded Medicare/commercial coverage for novel assays like ColoSense and NASHnext, enhance market access and accelerate adoption of Labcorp's new tests. However, persistent reimbursement pressures and evolving payer policies, including potential average selling price declines and delayed coverage for novel tests, could impact profitability. Significant regulatory hurdles and extensive evidence generation requirements for new diagnostic indications could impede timely rollout and broad adoption of Labcorp's innovative tests. Intensifying competition from both established players and new entrants in the diagnostics and early detection space may lead to pricing pressures and increased commercialization costs.

3 Main Long-Term Bull Details

Labcorp's strategic focus and market-leading portfolio in high-growth specialty areas such as oncology (liquid biopsies, MRD solutions), neurology (Alzheimer's testing), autoimmune disease, and women's health position it for accelerated growth, as these segments are expected to grow 2 to 3 times faster than the broader diagnostics market.
The company's strategy of being a "partner of choice" for health systems and regional/local laboratories, coupled with an active pipeline of such deals, enables it to continuously expand its patient and provider networks, increase access to its broad test portfolio, and drive volume growth.
Labcorp's significant investments and collaborations in advanced technologies, including AI and robotics, are enhancing customer experiences (e.g., MyLabcorp app, Epic Aura collaboration), improving operational efficiency (e.g., streamlined operations), and accelerating drug discovery, creating a sustainable competitive advantage and driving future growth.

3 Main Long-Term Bear Details

Ongoing regulatory changes and initiatives like PAMA (Protecting Access to Medicare Act) pose potential headwinds, as they could impact reimbursement rates for laboratory testing. The actual effect on Labcorp will depend heavily on the participation rate of other laboratories in data reporting, creating potentially less favorable rates if participation is low.
Both the diagnostics and biopharma laboratory services markets are highly competitive. Aggressive pricing dynamics, particularly in the CRO market, could pressure margins and make it challenging to maintain market share, despite Labcorp's scale and differentiation. In the consumer health segment, Labcorp is selectively choosing not to compete in some areas due to aggressive pricing and uncertainty regarding pricing floors.
While biotech funding is recovering, broader macroeconomic conditions and budgetary uncertainties can still impact R&D spending, leading to potential fluctuations in demand for Labcorp's biopharma services and overall organic revenue growth.

Competitors And Differentiation: Labcorp operates in highly competitive markets. In diagnostics, its closest peer is often considered Quest Diagnostics. In the contract research organization (CRO) market, competitors include companies like IQVIA, Medpace, Charles River Laboratories (CRL), and Fortrea (its spun-off clinical development business). Labcorp differentiates itself through several key strategies: a broad and specialized test portfolio, offering over 6,500 diagnostic tests with a strong focus on high-growth specialty areas like oncology, neurology, autoimmune disease, and women's health; strategic partnerships, aiming to be a "partner of choice" for health systems and regional/local laboratories; leveraging technology and innovation, utilizing AI and advanced technologies to improve customer experience and enhance productivity; a growing consumer focus through Labcorp OnDemand and the MyLabcorp app; and integrated services, providing both diagnostic laboratory services and biopharma laboratory services for comprehensive solutions.
Recent Performance & What The Market'S Focused On: Labcorp delivered a strong second quarter in 2026, with enterprise revenue growing 5.8% to $3.7 billion, adjusted operating margin expanding 70 basis points to 15.8%, and adjusted earnings per share growing 14.9% to $4.99. Free cash flow was $314 million. The company raised the midpoint of its full-year 2026 enterprise revenue and adjusted EPS guidance, reflecting confidence in continued profitable growth. Diagnostics revenue increased 5.5% to $2.9 billion, with organic growth of 3.6%, driven by specialty testing. Biopharma Laboratory Services (BLS) revenue increased 6.5% to $836 million, with a strong book-to-bill of 1.14 in the quarter. The market is focused on Labcorp's ability to sustain strong organic growth in Diagnostics, particularly in specialty areas, and the continued momentum in its BLS segment, especially Central Labs. Investors are also closely watching the impact of PAMA and the progress of the RESULTS Act, as well as the company's capital allocation strategy, including acquisitions and share repurchases. The successful adoption of new consumer offerings like ColoSense and the MyLabcorp app, and the ongoing integration of AI and technology to enhance efficiency and customer experience, are also key areas of market interest.

Revenue Segments And Estimated Mix: Diagnostics — Mix: ~77% (Q2 2026 revenue of $2.9 billion out of $3.7 billion total); Source: Q2 2026 transcript; Trend: Increased 5.5% YoY, with 3.6% organic growth
Biopharma Laboratory Services (BLS) — Mix: ~23% (Q2 2026 revenue of $836 million out of $3.7 billion total); Source: Q2 2026 transcript; Trend: Increased 6.5% YoY, with 6.2% organic constant currency growth; Central Labs grew 7.6% organic constant currency
Product Brands: Labcorp OnDemand
MyLabcorp
ColoSense
Plasma Detect Genome MRD
NASHnext
Marker by Labcorp Genetic Health Panel
Labcorp Fentanyl Urine Visual Test
Integrated Genetics
Integrated Oncology

Bull / Bear Details

Labcorp (LH) demonstrates robust growth, driven by strong Q2 2026 financial performance, raised full-year guidance, and strategic expansion in high-growth speci

Thesis

Labcorp (LH) demonstrates robust growth, driven by strong Q2 2026 financial performance, raised full-year guidance, and strategic expansion in high-growth specialty diagnostics (oncology, neurology) and biopharma services. Leveraging AI and strategic partnerships enhances efficiency and customer experience. While competitive pricing and regulatory uncertainties like PAMA persist, diversified growth and margin expansion support a positive outlook as of 2026-10-15.

Bull case

Labcorp delivered a very strong Q2 2026, with enterprise revenue up 5.8%, adjusted EPS growing 14.9%, and operating margins expanding 70 basis points. Management raised full-year 2026 guidance for both revenue and EPS, reflecting confidence in continued profitable growth and disciplined capital deployment. This demonstrates strong operational execution and positive momentum across its diversified businesses.
The company is achieving double-digit growth in key specialty areas like oncology (ColoSense, expanded portfolio) and neurology, which are expected to grow 2-3x faster than the broader diagnostics market. Strategic acquisitions (Parkview Health, Tribal Diagnostics) and a robust pipeline of hospital and regional lab deals further expand its patient and provider networks, driving volume growth.
Labcorp is aggressively leveraging AI and technology to enhance customer experiences and operational efficiency, exemplified by the AI-powered MyLabcorp app and broadened collaboration with Epic. The consumer business continues to deliver strong double-digit growth with innovative offerings like Marker by Labcorp Genetic Health Panel and at-home self-collection tests.

Bear case

The future impact of PAMA on reimbursement rates for laboratory testing remains a significant regulatory uncertainty. The actual effect on Labcorp will depend heavily on the participation rate of other laboratories in the data reporting survey. Additionally, the anticipated 30 basis point headwind from ACA changes to Diagnostics volume adds to potential reimbursement pressures.
The CRO market remains highly competitive, characterized by aggressive pricing dynamics that can impact margins. In the consumer health segment, Labcorp is selectively choosing not to compete in some areas due to aggressive pricing and uncertainty regarding pricing floors, indicating ongoing competitive challenges and potential pressure on profitability.
While Q2 2026 showed strong performance, broader macroeconomic conditions and budgetary uncertainties can still impact R&D spending, leading to potential fluctuations in demand for Labcorp's biopharma services. Unpredictable external factors, such as the previously noted adverse weather impact in Q1, could continue to pose risks to volume and revenue.

Bull / Bear Case

Bear Case: The future impact of PAMA on reimbursement rates for laboratory testing remains a significant regulatory uncertainty, with potential Medicare lab payment cuts of up to 15% annually for 2027-2029. The passage of the bipartisan RESULTS Act, aimed at mitigating these cuts, is uncertain. Additionally, an anticipated 30 basis point headwind from ACA changes to Diagnostics volume adds to potential reimbursement pressures. The CRO market remains highly competitive, characterized by aggressive pricing dynamics that can impact margins, leading Labcorp to selectively avoid some lower-margin consumer partnerships. Broader macroeconomic conditions and budgetary uncertainties can still impact R&D spending, leading to potential fluctuations in demand for Labcorp's biopharma services.
Bull Case: Labcorp delivered a very strong Q2 2026, with enterprise revenue up 5.8%, adjusted EPS growing 14.9%, and operating margins expanding 70 basis points. Management raised full-year 2026 guidance for both revenue and EPS, reflecting confidence in continued profitable growth and disciplined capital deployment. The company is achieving double-digit growth in key specialty areas like oncology and neurology, which are expected to grow 2-3x faster than the broader diagnostics market. Strategic acquisitions and a robust pipeline of hospital and regional lab deals further expand its patient and provider networks, driving volume growth. The Biopharma Laboratory Services segment shows strength, particularly in Central Labs, with a healthy book-to-bill ratio. Labcorp is also aggressively leveraging AI and technology to enhance customer experiences and operational efficiency, and its consumer business continues to deliver strong double-digit growth.
More Compelling & Why: Bull. Labcorp's Forward P/E ratio of approximately 15.5x is competitive, especially when compared to its pure-play CRO peer Medpace (Forward P/E ~31.95x - 35.35x). The strongest argument for the bull case is Labcorp's diversified business model, combining a robust Diagnostics segment with high-growth specialty testing and a strong Biopharma Laboratory Services segment, which provides resilience against market-specific headwinds. My view would flip to bear if PAMA cuts for 2027-2029 are implemented without significant mitigation, leading to a material negative impact on Labcorp's profitability and future guidance.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
PAMA Data Reporting Survey Participation and RESULTS Act Progress	PAMA's implementation in 2027 could significantly impact Medicare reimbursement rates for diagnostic tests. The RESULTS Act aims to provide a legislative fix, making progress crucial for mitigating potential headwinds.	Updates from CMS or industry trade groups (ACLA) on the number and type of laboratories that submitted PAMA data by the July 31, 2026 deadline. Progress on the RESULTS Act (e.g., CBO score, legislative traction).	Bullish if a significant number of hospital and other laboratories reported PAMA data, potentially leading to more favorable market-based rates. Bullish if the RESULTS Act gains legislative traction. Bearish if participation is low or the RESULTS Act stalls.	CMS announcements, ACLA press releases, Labcorp's Q3 2026 earnings call (expected late October/early November 2026) for management commentary on PAMA insights (expected in October).	ACLA website for industry updates, Congressional Record for RESULTS Act progress.	FiscalNote: Legislative tracking for healthcare bills.
Biopharma Laboratory Services (BLS) Segment Quarterly Book-to-Bill Ratio	A strong book-to-bill ratio indicates future revenue visibility and sustained demand for Labcorp's drug development services, particularly Central Labs, which is a key driver for the BLS segment.	The reported BLS quarterly book-to-bill ratio in Q3 2026 earnings and subsequent quarters. Specifically, if it remains at or above 1.0, and if the trailing 12-month book-to-bill remains above 1.0.	Bullish if the quarterly book-to-bill remains at or above 1.0, indicating continued strong demand and future revenue growth. Bearish if it declines below 1.0.	Labcorp's Q3 2026 earnings release and conference call (expected late October/early November 2026).
Progress on Hospital & Regional Lab Acquisitions and Partnerships	Strategic acquisitions and partnerships are a core component of Labcorp's growth strategy, expanding its network, increasing test volumes, and enhancing market presence, as evidenced by recent deals and a robust pipeline.	Announcements regarding new strategic collaborations or acquisitions from Labcorp's 'robust pipeline of deals'.	Bullish if new, significant hospital or regional lab deals are announced, indicating successful execution of the growth strategy. Bearish if announced deals are delayed or no new material partnerships are disclosed.	Labcorp press releases, SEC filings (Form 8-K for material agreements), and Q3 2026 earnings call (expected late October/early November 2026).	Industry news outlets (e.g., Fierce Healthcare, Modern Healthcare) for announcements of hospital system partnerships.	MergerMarket: Healthcare services M&A activity.
Growth in Specialty Diagnostics (Oncology, Neurology, Autoimmune Disease, Women's Health)	These high-growth, higher-margin specialty areas are central to Labcorp's strategy, driving overall Diagnostics segment performance and margin expansion, and attracting new health system and provider customers.	Commentary in future earnings calls on specific growth rates for these specialty areas (e.g., double-digit growth), new test launches (e.g., ColoSense adoption, new companion diagnostics), and expanded access initiatives.	Bullish if these specialty areas continue to show strong double-digit growth (e.g., >10%) and contribute significantly to overall Diagnostics organic growth. Bearish if growth decelerates or new launches fail to gain traction.	Labcorp's Q3 2026 earnings release and conference call (expected late October/early November 2026).	Google Trends: 'ColoSense', 'Labcorp oncology', 'Labcorp neurology' search volume.	IQVIA / Symphony Health: CPT code utilization for specific specialty diagnostic tests.
Diagnostics Segment Organic Volume Growth (and Tests per Accession)	Organic volume growth reflects underlying market demand and Labcorp's ability to capture market share, while 'tests per accession' indicates increasing utilization per patient, both crucial for sustained revenue growth in the largest segment.	Diagnostics segment organic volume growth and commentary on 'tests per accession' in future earnings calls. Specifically, if organic volume growth remains strong (e.g., >1.8% organic volume growth from Q2) and tests per accession continue to increase.	Bullish if Diagnostics organic volume growth remains robust (e.g., at or above 1.8%) and 'tests per accession' continues to show consistent, slight growth. Bearish if organic volume growth decelerates significantly or 'tests per accession' declines.	Labcorp's Q3 2026 earnings release and conference call (expected late October/early November 2026).		IQVIA / Symphony Health: Overall diagnostic test volume trends.

Key Reported Metrics, Reratings Triggers & Results3 rows

Adjusted EPS growth is a key bottom-line metric reflecting the company's overall profitability, operational efficiency, and ability to translate revenue growth

Upcoming print · 2026-10-28

Key reported metrics			Rerating thresholds
Metric	Last period	Why it matters	What's needed for rerating	Rerating context	Earnings date
Adjusted EPS Growth	$4.99 (15% y/y growth)	Adjusted EPS growth is a key bottom-line metric reflecting the company's overall profitability, operational efficiency, and ability to translate revenue growth into shareholder value.	For Labcorp Holdings Inc. (LH) to rerate higher, the company would need to report Q3 2026 Adjusted EPS growth significantly above the 11.2% consensus estimate, ideally in the mid-to-high teens (e.g., 14-16% or higher). Additionally, Labcorp would need to simultaneously raise its full-year 2026 Adjusted EPS guidance beyond the current $18.10-$18.55 range.	Achieving mid-to-high teens Adjusted EPS growth for Q3 and raising full-year guidance would signal accelerating operational efficiency and successful execution of strategic initiatives. This would differentiate Labcorp in a competitive market, validate its investment thesis, and potentially lead to a higher valuation multiple as investors gain confidence in its long-term profitability and ability to overcome industry headwinds like PAMA.	2026-10-28
Diagnostics Segment Revenue Growth (Organic)	$2.9 billion (3.6% organic revenue growth)	As the largest revenue contributor, organic growth in Diagnostics reflects core market demand, successful strategic initiatives like specialty testing, and the impact of acquisitions.	For Labcorp's stock to rerate higher, its Diagnostics Segment Revenue Growth (Organic) metric needs to hit 5% or higher. This would represent a significant acceleration from the 3.6% reported in Q2 2026 and demonstrate strong progress towards the company's full-year 2026 Diagnostics Laboratories segment revenue growth guidance of 5.3% to 6.0%. Achieving a figure closer to the upper end of this guidance would be particularly impactful, especially when compared to peer Quest Diagnostics' projected 8.1% revenue growth for Q3 2026.	Achieving 5% or higher organic growth in Diagnostics signifies successful strategic execution in specialty testing and hospital partnerships. This acceleration validates Labcorp's growth thesis, enhances competitive standing against peers, and would likely drive a higher valuation multiple from investors.	2026-10-28
Biopharma Laboratory Services (BLS) Revenue Growth (Organic Constant Currency)	$836 million (6.2% organic constant currency growth)	This metric indicates the health and growth of Labcorp's contract research business, a key driver for the CRO theme. Strong organic growth signals robust demand and successful execution in Central Labs, validating future revenue growth.	For Labcorp's stock to rerate higher, its Biopharma Laboratory Services (BLS) Revenue Growth (Organic Constant Currency) metric needs to hit at least 6.5% in Q3 2026. This would demonstrate sustained acceleration from the implied upper end of the company's full-year 2026 organic constant currency guidance of 5.0% (derived from 5.5%-6.5% total BLS growth guidance minus a 1.5% foreign currency tailwind). Additionally, a strong BLS quarterly book-to-bill ratio above 1.0, following Q2's 1.14, is crucial to signal future revenue growth.	Achieving at least 6.5% organic constant currency growth in BLS would signal robust demand and effective execution in Labcorp's drug development services, particularly Central Labs, validating its strategic focus and competitive strength in the highly competitive CRO market. This continued acceleration and strong book-to-bill would reinforce the investment thesis, indicating strong backlog conversion and future revenue visibility, potentially leading to a higher valuation.	2026-10-28

Last reported · 2026-07-30

Key reported metrics			Rerating thresholds			Earnings results
Metric	Last period	Why it matters	What's needed for rerating	Rerating context	Earnings date	Actual reported	Hit target?	Notes
Adjusted EPS Growth	10.6%	Adjusted EPS growth is a key bottom-line metric reflecting the company's overall profitability, operational efficiency, and ability to translate revenue growth into shareholder value.	Labcorp Holdings Inc. (LH) would likely need to report Q2 2026 Adjusted EPS growth significantly above the 10.1% consensus estimate, ideally in the mid-teens (e.g., 14-15% or higher). Additionally, the company would need to simultaneously raise its full-year 2026 Adjusted EPS guidance beyond the current $17.70-$18.35 range, which currently implies approximately 10% growth at the midpoint.	Achieving mid-teens Adjusted EPS growth for Q2 and raising full-year guidance would signal accelerating operational efficiency and successful execution of strategic initiatives. This would differentiate Labcorp in a competitive market, validate its investment thesis, and potentially lead to a higher valuation multiple as investors gain confidence in its long-term profitability and ability to overcome industry headwinds.	2026-07-30	$4.99 (15% y/y growth)	Yes	Labcorp's adjusted earnings per share grew 15% to $4.99, meeting the mid-teens growth target. The company also raised its full-year 2026 adjusted EPS guidance range to $18.10 to $18.55, with an implied growth rate at the midpoint of more than 11%, which is beyond the prior guidance range.
Diagnostics Segment Revenue Growth (Organic)	2.9%	As the largest revenue contributor, organic growth in Diagnostics reflects core market demand, successful strategic initiatives like specialty testing, and the impact of acquisitions.	For Labcorp's stock to rerate higher, its Diagnostics Segment Revenue Growth (Organic) metric needs to hit 5% or higher. This would represent a significant acceleration from the 2.9% reported in Q1 2026 and demonstrate that Labcorp is effectively capitalizing on market opportunities, especially when compared to its peer Quest Diagnostics' recent Q2 2026 organic revenue growth of 10.0%.	Achieving 5% or higher organic growth in the Diagnostics segment is crucial as it signifies that Labcorp's strategic initiatives, such as expanding specialty testing and hospital partnerships, are successfully driving core business performance. This acceleration would validate the company's growth thesis, enhance its competitive standing against peers, and likely lead to a higher valuation multiple from investors.	2026-07-30	$2.9 billion (3.6% organic revenue growth)	No	The Diagnostics segment reported organic revenue growth of 3.6%, which, while considered strong by management and above the typical market growth of 1-2%, did not meet the rerating trigger of 5% or higher. Management emphasized focusing on high-growth, higher-margin specialty areas, which contributed to margin expansion.
Biopharma Laboratory Services (BLS) Revenue Growth (Organic Constant Currency)	3.7%	This metric indicates the health and growth of Labcorp's contract research business, a key driver for the CRO theme. Strong organic growth signals robust demand and successful execution in Central Labs.	For Labcorp's stock to rerate higher, its Biopharma Laboratory Services (BLS) Revenue Growth (Organic Constant Currency) metric needs to hit at least 4.5% in Q2 2026. This would represent an acceleration from the current 3.7% and exceed the implied upper end of the company's full-year 2026 guidance range (approximately 3.9% organic constant currency, derived from the 3.8%-5.4% total BLS growth guidance which includes a 1.5% foreign currency tailwind). Additionally, a strong BLS quarterly book-to-bill ratio above 1.0, demonstrating sequential improvement from Q1's 0.94, is crucial to signal future revenue growth. Peer performance, such as Medpace's 17% YoY revenue growth and 1.13x book-to-bill, sets a high bar for the CRO sector, making an accelerated organic growth rate for Labcorp's BLS particularly impactful.	Accelerated BLS organic constant currency growth signals robust demand and effective execution in Labcorp's drug development services, particularly Central Labs. This validates the company's strategic focus and competitive strength in the highly competitive CRO market, indicating strong backlog conversion and future revenue visibility. Exceeding expectations would reinforce the investment thesis, potentially leading to a higher valuation.	2026-07-30	$836 million (6.2% organic constant currency growth)	Yes	The BLS segment reported organic constant currency revenue growth of 6.2%, significantly exceeding the 4.5% rerating trigger. The quarterly book-to-bill ratio was strong at 1.14, improving sequentially from Q1's 0.94 and remaining above 1.0, indicating robust future revenue visibility. Management raised the midpoint of the BLS revenue guidance by 140 basis points for the full year, driven by continued strength in Central Labs and a more favorable outlook for Early Development.

Key Questions

Given CMS's release of preliminary PAMA rates for 2027-2029, which Labcorp views as unrepresentative and potentially leading to steep cuts, will the company's r

Given CMS's release of preliminary PAMA rates for 2027-2029, which Labcorp views as unrepresentative and potentially leading to steep cuts, will the company's reaffirmed 2026 guidance and long-term outlook prove resilient, and will the bipartisan RESULTS Act gain legislative traction to mitigate these future reimbursement pressures?

Question 2: Can Labcorp sustain the strong momentum in its Biopharma Laboratory Services (BLS) segment, particularly in Central Labs, by effectively converting its $8.7 billion backlog into revenue and maintaining a book-to-bill ratio above 1.0 in the coming quarters, especially following recent acquisitions?
Question 3: Will Labcorp continue to drive profitable growth in its Diagnostics segment by sustaining double-digit growth in high-margin specialty testing areas and effectively executing on its robust pipeline of hospital and regional laboratory acquisitions and partnerships, leading to further margin expansion?

Earnings Transcript Summary2 rows

2026-07-30 · 2026Q2 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Strengthening leadership in specialty testing: Management highlighted double-digit revenue growth in specialty areas like oncology, neurology, autoimmune disease, and women's health, and expanding the portfolio with new tests such as ColoSense and strategic partnerships. This focus aims to drive higher-value growth and attract new health system and provider customers. 2. Being a partner of choice for health systems and regional/local laboratories: Management emphasized the critical role these partnerships play in providing health systems and providers greater access to Labcorp's high-quality, cost-effective laboratory services, scientific expertise, and broad testing portfolio. Recent acquisitions of select outreach laboratory services from Parkview Health and Tribal Diagnostics, along with a robust pipeline of deals, demonstrate this strategic priority. 3. Shaping the future through technology and innovation to improve customer experience, enhance productivity, and transform the business: Adam Schechter discussed broadening collaboration with Epic to make Labcorp's diagnostic tests available on Epic's Aura platform, enhancing patient service center experiences, and launching the AI-powered MyLabcorp app for scheduling, viewing results, and gaining health insights.	Call Takeaway & ToneThe overall takeaway of the call was positive and confident. Labcorp delivered another strong financial quarter with solid revenue growth, significant margin expansion, and double-digit adjusted EPS growth. Management expressed confidence in their strategic priorities, including strengthening leadership in specialty testing, expanding partnerships with health systems, and leveraging technology and AI to enhance customer experiences and productivity. The company raised its full-year 2026 revenue and EPS guidance, reflecting optimism for continued profitable growth and disciplined execution. The tone was consistently upbeat, emphasizing high-quality growth and long-term value creation.	Prior Quarter'S Y/Y Growth By SegmentIn Q1 2026, enterprise revenue increased 5.8%. Diagnostics revenue increased 5%. Biopharma Laboratory Services (BLS) revenue increased 8.2%. Within BLS, Central Labs grew 11% (or 4.9% organic constant currency), and Early Development revenue grew 0.7% on an organic constant currency basis.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Diagnostics organic growth and its drivers, including volume calculation and peer comparison: Analysts questioned the 3.6% organic growth, how it compares to the market and peers, and how volume is calculated (accessions vs. tests). Management responded that the 3% volume growth (1.8% organic) does not include test-per-accession increases, implying higher actual test volume. They stated Labcorp is growing substantially more than the typical market growth of 1-2% due to hospital and regional lab deals, and they are focusing on high-growth, higher-margin areas like specialty testing, which explains their margin improvement despite peer comparisons. 2. Biopharma Laboratory Services (BLS) segment performance, particularly Early Development's turnaround and bookings: Analysts inquired about the revenue improvement in Early Development (restructuring vs. market), Central Labs' strength, and the decomposition of bookings. Management explained that Early Development's 2.7% organic constant currency growth was due to strategic decisions being largely completed and implemented, strong RFPs, consistent win rates, and more on-time study starts. The overall BLS book-to-bill of 1.14 for the quarter (1.03 trailing 12 months) was primarily driven by Central Laboratories, boding well for future growth. 3. ACA impact and bad debt/collectibility: Analysts asked about the potential headwind from changes around ACA and Medicaid, and concerns about deterioration in collectibility of the insured population, as noted by hospital peers. Management reiterated their full-year 2026 guidance includes a 30 basis point impact to Diagnostics segment volume from ACA, noting the Q2 impact was a slight headwind of 20-30 basis points. They stated that bad debt as a percentage of revenue for Diagnostics remains consistent with prior year and historical benchmarks (less than 5%), and they are not seeing the same level of collectibility deterioration as some other customers, potentially due to their patient mix.	Revenue SegmentsEnterprise revenue grew 5.8%. Diagnostics revenue increased 5.5%. Biopharma Laboratory Services (BLS) revenue increased 6.5%. Within BLS, Central Lab Services delivered strong revenue growth of 7.6% on an organic constant currency basis, and Early Development grew 2.7% on an organic constant currency basis.

2026-04-30 · 2026Q1 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Being a partner of choice for health systems and regional/local laboratories: Management emphasized expanding patient and provider networks, increasing access to their broad test portfolio (including specialty diagnostics), and driving volume growth through strategic collaborations and acquisitions, such as with Children's Hospital of Philadelphia and Crouse Health. 2. Leading in specialty testing: The company is focused on key growth areas like oncology, women's health, neurology, and autoimmune disease, expecting these areas to grow 2 to 3 times faster than the broader diagnostics market. They highlighted double-digit growth in neurology (driven by Alzheimer's testing) and oncology (supported by liquid biopsy tests and MRD solutions). 3. Utilizing advanced technologies, including AI and robotics: Management is focused on leveraging these technologies to enhance customer experiences and improve operational efficiency and productivity. Examples include expanding collaboration with PathAI for digital pathology, developing an AI-powered real-world data platform with Amazon Web Services and Datavant for Alzheimer's research, and a strategic collaboration with Optum.ai to streamline laboratory operations.	Call Takeaway & ToneThe overall takeaway of the call was positive, with Labcorp reporting a strong start to 2026, marked by solid revenue growth and margin expansion across both its Diagnostics and Biopharma Laboratory Services segments. Management expressed confidence in their strategic priorities, including partnerships with health systems, leadership in specialty testing, and the adoption of advanced technologies like AI. The company raised its full-year 2026 guidance, reflecting optimism for continued profitable growth and disciplined capital deployment. The tone was confident and optimistic.	Prior Quarter'S Y/Y Growth By SegmentIn Q4 2025, enterprise revenue increased 5.6%. Diagnostics Laboratories segment revenue increased 5.5%. Biopharma Laboratory Services (BLS) revenue rose 3.4%, with Central Labs revenue growing 11.1% and Early Development revenue declining 13.5%.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Impact of weather and ACA exchange on Diagnostics volume: Analysts questioned the impact of adverse weather in Q1 and potential headwinds from the ACA exchange. Management estimated a $15 million impact from weather, which would have brought organic volume growth closer to 2% without it. For ACA, they maintained their full-year estimate of a 30 basis point volume impact, noting the Q1 impact was immaterial but they continue to monitor enrollment and utilization. 2. Bookings trends in BLS, especially Central Labs vs. Early Development, and confidence in future book-to-bill: Analysts inquired about the BLS bookings and the quarterly book-to-bill ratio. Management expressed confidence in the BLS momentum, particularly Central Labs' growth, and stated that the Q1 book-to-bill of 0.94 was primarily due to timing, expecting sequential improvement in Q2 and a full-year book-to-bill to remain above 1.0. 3. PAMA survey and RESULTS Act progress: Analysts asked for updates on the PAMA survey and the RESULTS Act. Management reiterated their support for the RESULTS Act as the appropriate path forward and is awaiting a CBO score and CMS technical assistance. They noted that Labcorp would submit its data for PAMA, and the impact would depend on the number of other laboratories (including hospital labs) that also report, as more reporting would lessen the impact on Labcorp.	Revenue SegmentsEnterprise revenue increased 5.8%. Diagnostics revenue increased 5%. Biopharma Laboratory Services (BLS) revenue increased 8.2%, driven by strong growth in Central Labs of 11% (or 4.9% organic constant currency). Early Development revenue grew 0.7% on an organic constant currency basis, partially offset by strategic actions of 1%.

Transcript Tidbits2 rows

2026-07-30

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)
About Expanding Eligible MarketLabcorp broadened its specialty test portfolio across oncology, neurology, autoimmune disease, and women's health, which collectively delivered double-digit revenue growth in the first half of the year and helped secure new health system and provider customers. The company launched ColoSense nationwide, the first FDA-approved, RNA-based colorectal cancer screening test with at-home collection, increasing patient access and enabling earlier detection. Labcorp expanded nationwide access to Roche's FDA-approved companion diagnostic for prostate cancer. It also signed an agreement to broaden nationwide access to myOLARIS-KTdx, a noninvasive test for kidney transplant surveillance. Labcorp's blood-based test, NASHnext, secured Medicare coverage, expanding access for patients at risk of liver disease. The company completed the acquisition of select outreach laboratory services from Parkview Health and Tribal Diagnostics, a clinical laboratory serving communities in Oklahoma and Texas. Labcorp was awarded a Department of Defense contract to provide laboratory testing for service members and their families across military hospitals worldwide. The consumer business delivered strong double-digit growth, driven by increasing demand for consumer-initiated testing, innovative offerings, and digital experiences. The company launched Marker by Labcorp Genetic Health Panel through Labcorp OnDemand and Canada's first at-home self-collection test for women's fertility-related hormones and men's testosterone levels. Labcorp broadened its collaboration with Epic, making its 6,500-plus diagnostic tests available on Epic's Aura platform.	About CompetitionThe CRO market remains highly competitive, characterized by aggressive pricing dynamics. Labcorp is focusing on high-growth, higher-margin segments like specialty oncology, women's health, autoimmune disease, and neurology, and has opted not to compete in some lower-margin consumer partnerships due to aggressive pricing and uncertainty regarding pricing floors. Adam Schechter noted that the market typically grows at 1% to 2%, and Labcorp is growing substantially more, partly due to hospital and regional laboratory deals.	About The Broader IndustryThe broader industry is facing potential impacts from changes around ACA and Medicaid, with Labcorp anticipating a 30 basis point headwind to its Diagnostics segment volume for the full year 2026. Hospitals are feeling additional pressure, not just from ACA, but also from the upcoming PAMA implementation next year. The PAMA data submission date was July 31st, and significant insight into overall laboratory participation is expected around October. The RESULTS Act continues to be a focus for the trade group and Labcorp, with bipartisan support, though its passage is uncertain due to upcoming elections. There is a consistent and slight growth in tests per accession, supported by structural factors like the aging population, health and wellness trends, and advancements in diagnostic testing.	Where Things Are HeadedLabcorp raised the midpoint of its enterprise revenue range and adjusted EPS range for the full year 2026 by $42 million and $0.30, respectively. The company expects specialty areas in Diagnostics to continue growing faster than the routine business. Labcorp has a robust pipeline of deals to support its long-term growth strategy. The company is leveraging technology and AI to improve customer experience, enhance productivity, and transform its business, including the recently launched AI-powered MyLabcorp app. Labcorp remains confident in its long-term growth trajectory and is focused on delivering profitable growth and strong free cash flow. The BLS segment margin is expected to expand more than Diagnostics in 2026 versus 2025. The Launchpad initiative remains on track. Capital expenditures are expected to be approximately 4% of revenue for the full year. Labcorp plans to discuss its future in more detail at its Analyst Day in September.	Updates On ThemeDiagnostics	Broader Themes EmergingThe deep integration of AI and advanced technology is emerging as a significant theme across the industry, with Labcorp leveraging AI to enhance customer experiences (MyLabcorp app), improve productivity, and transform its business. There is also a growing trend in consumer-initiated testing and digital health experiences, as evidenced by Labcorp's strong double-digit growth in its consumer business and new offerings like the Marker by Labcorp Genetic Health Panel and at-home self-collection tests.	Bullish-Leaning Quotes (Short)Labcorp delivered another very strong quarter driven by solid revenue growth, margin expansion, and progress across our strategic priorities. Our Diagnostics and Biopharma Laboratory Services businesses both performed well, advancing strategic initiatives and expanding technological capabilities that continue to drive growth. Collectively, in the first half of the year, these specialty areas delivered double-digit revenue growth and helped us to win new health system and provider customers. Our consumer business continued to deliver strong double-digit growth. We are raising the midpoint of our enterprise revenue range and our adjusted EPS range by $42 million and $0.30, respectively. We remain confident in our long-term growth trajectory.	Bearish-Leaning Quotes (Short)The impact from ACA during Q1 was immaterial. Subsequently, in the second quarter, it was a slight headwind of about 20 to 30 basis points of the diagnostic volume. The impact of PAMA on Labcorp will be highly dependent upon the number of other laboratories, including hospital laboratories that report their data. In some of the lower-margin segments such as some of the partnerships in the consumer area, we've not focused because we have so many other growth opportunities.

2026-04-30

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketLabcorp announced a nationwide strategic collaboration with Children's Hospital of Philadelphia to expand access to cutting-edge diagnostics for pediatric patients. The company completed its acquisition of select assets of Crouse Health's Laboratory Alliance of Central New York and executed an agreement to manage their inpatient laboratories. Labcorp is also on track to close its acquisition of select outreach laboratory services from Parkview Health in Indiana and Northwest Ohio. The company maintains an active pipeline of hospital and regional local laboratory deals to support long-term growth. Specialty testing in oncology, women's health, neurology, and autoimmune disease is a key focus, with these areas expected to grow 2 to 3 times faster than the broader diagnostics market. Labcorp is collaborating with Illumina to broaden access to advanced genomic testing in oncology, particularly in community care settings, and expanded nationwide access to an FDA-approved companion diagnostic for platinum-resistant ovarian cancer. The company also launched the Labcorp Fentanyl Urine Visual Test. In Consumer Health, which is delivering double-digit growth, Labcorp OnDemand launched new tests for insulin resistance and pancreatic function, as well as customizable men's and women's health tests. The MyLabcorp secure mobile app, launching in May, will provide personalized test results and health data with clinical guidance to tens of millions of customers, and its AI assistant will simplify appointment scheduling and payments.	About CompetitionThe CRO market remains highly competitive, with aggressive pricing dynamics described as a 'knife fight every quarter,' and unfavorable mix shifts continuing to impact margins across the industry. Labcorp is supportive of initiatives like CRUSH that aim to create a level playing field by reducing fraud, waste, and abuse in the industry. In the consumer business, Labcorp has opted not to compete in some segments due to strong volume at current pricing without a clear floor for pricing, indicating competitive pressures in those areas.	About The Broader IndustryThe broader industry is grappling with policy questions such as the CRUSH initiative by CMS, which aims to reduce fraud, waste, and abuse in laboratory testing. Labcorp supports efforts to create a level playing field but encourages CMS to be thoughtful to avoid impeding Medicare patient access to medically necessary testing. The company continues to monitor the impact of ACA exchange changes, with a 30 basis point volume impact to diagnostics still estimated for the full year 2026, despite immaterial impact in Q1. Labcorp is actively pushing for the implementation of the RESULTS Act, which aims to provide a long-term permanent fix for PAMA. The impact of PAMA on Labcorp will depend heavily on the number of other laboratories, including hospital laboratories, that report their data. The biopharma trial volume is rebounding, supported by biotech funding recovery and increased R&D investment and outsourcing by large pharmaceutical companies. Geopolitical factors are driving the re-shoring of Master Service Agreements (MSAs) to Western CROs. There is also an accelerated AI integration and deployment in CRO operations, driving efficiency and accelerating drug discovery.	Where Things Are HeadedLabcorp is raising the midpoint of its enterprise revenue range by approximately $30 million and the midpoint of its EPS range by $0.13 for the full year 2026. The company expects specialty areas in Diagnostics to grow 2 to 3 times faster than the broader diagnostics market. The MyLabcorp mobile app is launching in May. Labcorp is expanding its collaboration with PathAI to deploy an FDA-cleared digital pathology platform and is developing a new AI-powered real-world data platform with Amazon Web Services and Datavant to accelerate Alzheimer's research. A strategic collaboration with Optum.ai will apply AI capabilities to streamline laboratory operations and enhance patient and provider experiences. Strategic actions in the Early Development business are expected to be largely complete by the end of the second quarter. The BLS segment's quarterly book-to-bill is expected to improve sequentially in the second quarter and remain above 1 for the rest of the year. Labcorp will hold an Investor Day in New York City on September 10. The company remains focused on higher-margin business and is optimistic about its growth prospects and strategic priorities. Adam Schechter believes that if PAMA is implemented in January, it will likely increase the pipeline of deals for local and regional laboratories due to increased stress on these systems. Labcorp will continue to invest in bringing new products to market and in appropriate advertising for its OnDemand consumer business.	Updates On ThemeCROs:	Broader Themes EmergingThe integration of advanced technologies, particularly Artificial Intelligence (AI) and robotics, is a significant emerging theme across the industry. Labcorp is utilizing AI to enhance customer experiences (e.g., MyLabcorp's AI assistant), improve operational efficiency and productivity (e.g., digital pathology platform with PathAI, streamlining laboratory operations with Optum.ai), and accelerate drug development (e.g., AI-powered real-world data platform for Alzheimer's research with AWS and Datavant).	Bullish-Leaning Quotes (Short)We are off to a strong start in 2026 with continued momentum in both our Diagnostics and Central Laboratory businesses and significant progress across our strategic growth priorities. Our financial results were strong in the first quarter. At an enterprise level, revenue reached $3.5 billion, increasing 6%. Margins improved more than 30 basis points and adjusted earnings per share grew 11%. We continue to have an active pipeline of hospitals and regional local laboratory deals to support our long-term growth strategy. In the Diagnostic business, we expect these specialty areas to grow 2 to 3x faster than the broader diagnostics market. Labcorp supported the development of more than 85% of new drugs approved by the FDA last year, including in these important specialty areas. Consumer Health, where we continue to deliver double-digit growth. MyLabcorp brings an individual test results and health data together with clinical guidance into a personalized experience to help consumers better understand their test results. MyLabcorp's AI assistant will also help simplify appointment scheduling and payments. Our BLS trailing 12-month book-to-bill remains healthy at 1.04. We are raising the midpoint of the enterprise revenue range by approximately $30 million and the midpoint of the EPS range by $0.13. We remain confident in our ability to deliver durable growth and long-term value for our shareholders. I am optimistic about our growth prospects before us and the strategic priorities that we've put in place.	Bearish-Leaning Quotes (Short)Volume was constrained by the impact from adverse weather, excluding which organic volume growth would have been closer to 2%. The impact that we saw in the first quarter was really immaterial, although it is perhaps too early to be able to draw any firm conclusion. The CRO market remains highly competitive, with aggressive pricing dynamics described as a 'knife fight every quarter,' and unfavorable mix shifts continuing to impact margins across the industry. In those areas, the reimbursement aren't necessarily quite where we'd like them to be at the moment. We've decided at this moment, there are some parts of it that although there is strong volume at the current pricing and not knowing the floor of the pricing that we're not necessarily going to compete at this time. The impact of PAMA of the RESULTS Act does not go through this year and PAMA actually comes to fruition next year, the impact to Labcorp will be highly dependent upon the number of other laboratories, including hospital laboratories that report their data. The estimated AOI impact is approximately $5 million to $10 million this year.	HiringDewey Steadman joined Labcorp in March as Senior Vice President of Investor Relations. Christin O'Donnell transitioned from leading Investor Relations to an important senior role in finance within the precision oncology and health systems division. Labcorp was recognized by Fortune as one of the most innovative companies for the fourth year in a row, highlighting its track record of scientific product and process innovations, which implies a workforce capable of driving such innovation.